Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes
AssigneeValipharma
InventorsKai Krohn, Annamari Ranki, Emilia Carlsson, Kristian Ovaska, Valtteri Hayry, Sampsa Hautaniemi
Life of this patent
Estimating the term…
Abstract
A method of identifying and treating a subject having a tumor with down regulation of NAV3 (neuronal navigator 3) and with over expression of at least one gene product. The method may be used to identify a subject with a colorectal tumor, brain tumor or tumor of epidermal keratinocytes and selecting a treatment for a subject with a colorectal tumor, brain tumor or tumor of epidermal keratinocytes.
Claims36
A method of demonstrating the malignant character of a tumor or cell subpopulation in a subject, the method comprising:
- i) determining NAV3 copy number change in a biological sample from the subject;
- and
- ii) determining over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin, and those listed in tables 8-12, in the biological sample or another biological sample from the subject;
- iii) demonstrating the malignant character of a tumor or cell subpopulation in a subject, when both NAV3 copy number change and over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 are present in the sample(s) from the subject.
A method of treating a subject having a tumor with NAV3 copy number change and with over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12, comprising a step, wherein at least one gene or gene product with over expression is affected.
A method of predicting a prognosis comprising:
- i) determining NAV3 copy number change in a biological sample from a subject;
- ii) determining over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12, in the biological sample or another biological sample from the subject;
- and
- iii) predicting a prognosis to the subject having both NAV3 copy number change and over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 in the sample(s).
A method of selecting a treatment to a subject, comprising:
- i) determining NAV3 copy number change in a biological sample from the subject;
- ii) determining over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12, in the biological sample or another biological sample from the subject;
- and
- iii) selecting a treatment to the subject having both NAV3 copy number change and over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 in the sample(s).
A use of NAV3 gene or gene product and at least one gene and/or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 for demonstrating the malignant character of a tumor or cell subpopulation with NAV3 copy number change and with over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12, in a subject.
A use of NAV3 gene or gene product and at least one gene and/or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 for predicting a prognosis to a subject.
A use of NAV3 gene or gene product and at least one gene and/or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 for selecting a treatment to a subject.
A use of at least one gene and/or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 for cancer therapy in a subject having a tumor with NAV3 copy number change.
A use of an antagonist, antibody or inhibitory molecule of at least one gene and/or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 for cancer therapy in a subject having a tumor with NAV3 copy number change and with over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12.
A method or use according to any one of the previous claims, wherein NAV3 copy number change is caused by a deletion, amplification or translocation of NAV3 gene or major part of it.
A method or use according to any one of the previous claims, wherein NAV3 deletion is a total or partial deletion of NAV3.
A method or use according to any one of the previous claims, wherein NAV3 copy number change is confirmed by FISH, LOH, CGH, sequencing analysis, immunohistochemistry, PCR, qPCR or tissue microarray.
A method or use according to any one of the previous claims, wherein the tumor is a colorectal tumor, brain tumor or tumor of epidermal keratinocytes.
A method or use according to any one of the previous claims, wherein the tumor is a bening tumor or a malignant tumor.
A method or use according to any one of the previous claims, wherein the tumor is a carcinoma.
A method or use according to any one of the previous claims, wherein the gene(s) and/or gene product(s) is activated, inactivated, overexpressed or underexpressed, or amount of the gene product is increased or decreased.
A method or use according to any one of the previous claims, wherein a presence of a tumor with NAV3 copy number change and with over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 is associated with lymph node metastases, high grade malignancy and/or poor survival.
A method or use according to any one of the previous claims, wherein the gene(s) selected from IL23R, GnRHR, beta-catenin, and those listed in tables 8-12, codes for a protein, which is a membrane protein, a protein regulating cellular processes, or a purine nucleotide binding protein.
A method or use according to any one of the previous claims, wherein the gene or gene product is selected from a group consisting of ARL11, SMR3B, FAM107A, MFSD2, BCLB6, CYSLTR2, VNN3, GNGT1, DNER, GnRHR, IL23R, beta-catenin, JAK1 and JAK3.
A method or use according to any one of the previous claims, wherein the gene or gene product is IL23R or/and GnRHR.
A method or use according to any one of the previous claims, wherein the gene product is a protein.
A diagnostic kit comprising tools for detecting NAV3 copy number change in a biological sample and tools for detecting over expression of at least one gene or gene product selected from IL23R, GnRHR, beta-catenin and those listed in tables 8-12 in a biological sample.
A method or use according to any one of the previous claims, wherein the brain tumor is a glioma.
Dependencies are inferred from the claim text.